Skip to content
Research Article Open access CC BY 4.0

Updates in the Epidemiology of Fatty Liver and its Consequences in Saudi Arabia: A Review

Badriah Mohammed Alanazi

Journal of Pharmaceutical Research International · pp. 39–46 · Published 8 Aug 2022

10.9734/jpri/2022/v34i46B36387

Abstract

The occurrence of non-alcoholic fatty liver disease has exponentially increased worldwide. A considerable majority of cases advance to non-Alcoholic Steatohepatitis in the nonexistence of therapeutic measures, which increases morbidity and death. Because the initial phases of the illness are frequently clinically unapparent, the identification of non-alcoholic fatty liver disease frequently rests on biochemical and radiographic studies. Concentrated life modifications that result in weight loss are the mainstay of the disease's management. Therapeutic treatments that could be additional to lifestyle changes once essential for case managing comprise insulin sensitizers, antioxidants, incretin-based pharmaceuticals, cholesterol depressing mediators, weight reduction therapies, bariatric surgery, and liver transplantation. For non-alcoholic fatty liver disease to be managed more effectively and lessen its worldwide impact, research must be conducted continuously.

Fatty liver NAFLD NASH epidemiology

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

9

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.